Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Circulating CD9+/GFAP+/survivin+ exosomes in malignant glioma patients following survivin vaccination.

Galbo PM Jr, Ciesielski MJ, Figel S, Maguire O, Qiu J, Wiltsie L, Minderman H, Fenstermaker RA.

Oncotarget. 2017 Oct 10;8(70):114722-114735. doi: 10.18632/oncotarget.21773. eCollection 2017 Dec 29.

2.

Exosomes Associated with Human Ovarian Tumors Harbor a Reversible Checkpoint of T-cell Responses.

Shenoy GN, Loyall J, Maguire O, Iyer V, Kelleher RJ Jr, Minderman H, Wallace PK, Odunsi K, Balu-Iyer SV, Bankert RB.

Cancer Immunol Res. 2018 Feb;6(2):236-247. doi: 10.1158/2326-6066.CIR-17-0113. Epub 2018 Jan 4.

3.

Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes.

Ku AW, Muhitch JB, Powers CA, Diehl M, Kim M, Fisher DT, Sharda AP, Clements VK, O'Loughlin K, Minderman H, Messmer MN, Ma J, Skitzki JJ, Steeber DA, Walcheck B, Ostrand-Rosenberg S, Abrams SI, Evans SS.

Elife. 2016 Dec 8;5. pii: e17375. doi: 10.7554/eLife.17375.

4.

Development of a Novel Antibody-Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1.

Thomas LJ, Vitale L, O'Neill T, Dolnick RY, Wallace PK, Minderman H, Gergel LE, Forsberg EM, Boyer JM, Storey JR, Pilsmaker CD, Hammond RA, Widger J, Sundarapandiyan K, Crocker A, Marsh HC Jr, Keler T.

Mol Cancer Ther. 2016 Dec;15(12):2946-2954. Epub 2016 Sep 26.

5.

Total cellular protein presence of the transcription factor IRF8 does not necessarily correlate with its nuclear presence.

Minderman H, Maguire O, O'Loughlin KL, Muhitch J, Wallace PK, Abrams SI.

Methods. 2017 Jan 1;112:84-90. doi: 10.1016/j.ymeth.2016.08.011. Epub 2016 Aug 28.

6.

Fluorescent In Situ Hybridization in Suspension by Imaging Flow Cytometry.

Maguire O, Wallace PK, Minderman H.

Methods Mol Biol. 2016;1389:111-26. doi: 10.1007/978-1-4939-3302-0_7.

7.

Quantifying MHC dextramer-induced NFAT activation in antigen-specific T cells as a functional response parameter.

Maguire O, Chen GL, Hahn TE, Brix L, McCarthy PL, Wallace PK, Minderman H.

Methods. 2017 Jan 1;112:75-83. doi: 10.1016/j.ymeth.2016.06.014. Epub 2016 Jun 17.

8.

Simultaneous, Single-Cell Measurement of Messenger RNA, Cell Surface Proteins, and Intracellular Proteins.

Soh KT, Tario JD Jr, Colligan S, Maguire O, Pan D, Minderman H, Wallace PK.

Curr Protoc Cytom. 2016 Jan 6;75:7.45.1-7.45.33. doi: 10.1002/0471142956.cy0745s75.

9.

Simultaneous assessment of NF-κB/p65 phosphorylation and nuclear localization using imaging flow cytometry.

Maguire O, O'Loughlin K, Minderman H.

J Immunol Methods. 2015 Aug;423:3-11. doi: 10.1016/j.jim.2015.03.018. Epub 2015 Apr 7.

10.

Flow cytometry and solid organ transplantation: a perfect match.

Maguire O, Tario JD Jr, Shanahan TC, Wallace PK, Minderman H.

Immunol Invest. 2014;43(8):756-74. doi: 10.3109/08820139.2014.910022. Review.

11.

Impaired innate immune alveolar macrophage response and the predilection for COPD exacerbations.

Berenson CS, Kruzel RL, Eberhardt E, Dolnick R, Minderman H, Wallace PK, Sethi S.

Thorax. 2014 Sep;69(9):811-8. doi: 10.1136/thoraxjnl-2013-203669. Epub 2014 Mar 31.

PMID:
24686454
13.

Nuclear translocation of nuclear factor of activated T cells (NFAT) as a quantitative pharmacodynamic parameter for tacrolimus.

Maguire O, Tornatore KM, O'Loughlin KL, Venuto RC, Minderman H.

Cytometry A. 2013 Dec;83(12):1096-104. doi: 10.1002/cyto.a.22401. Epub 2013 Oct 17.

14.

β-Sitosterol modulates TLR4 receptor expression and intracellular MyD88-dependent pathway activation in J774A.1 murine macrophages.

Valerio MS, Minderman H, Mace T, Awad AB.

Cell Immunol. 2013 Sep-Oct;285(1-2):76-83. doi: 10.1016/j.cellimm.2013.08.007. Epub 2013 Sep 7.

PMID:
24121260
15.

Human ovarian tumor ascites fluids rapidly and reversibly inhibit T cell receptor-induced NF-κB and NFAT signaling in tumor-associated T cells.

Simpson-Abelson MR, Loyall JL, Lehman HK, Barnas JL, Minderman H, O'Loughlin KL, Wallace PK, George TC, Peng P, Kelleher RJ Jr, Odunsi K, Bankert RB.

Cancer Immun. 2013 Jul 15;13:14. Print 2013.

16.

Down-regulation of signal transducer and activator of transcription 3 improves human acute myeloid leukemia-derived dendritic cell function.

Brady MT, Miller A, Sait SN, Ford LA, Minderman H, Wang ES, Lee KP, Baumann H, Wetzler M.

Leuk Res. 2013 Jul;37(7):822-8. doi: 10.1016/j.leukres.2013.04.002. Epub 2013 Apr 28.

17.

Neem oil limonoids induces p53-independent apoptosis and autophagy.

Srivastava P, Yadav N, Lella R, Schneider A, Jones A, Marlowe T, Lovett G, O'Loughlin K, Minderman H, Gogada R, Chandra D.

Carcinogenesis. 2012 Nov;33(11):2199-207. doi: 10.1093/carcin/bgs269. Epub 2012 Aug 21.

18.

The prolyl isomerase Pin1 targets stem-loop binding protein (SLBP) to dissociate the SLBP-histone mRNA complex linking histone mRNA decay with SLBP ubiquitination.

Krishnan N, Lam TT, Fritz A, Rempinski D, O'Loughlin K, Minderman H, Berezney R, Marzluff WF, Thapar R.

Mol Cell Biol. 2012 Nov;32(21):4306-22. doi: 10.1128/MCB.00382-12. Epub 2012 Aug 20.

19.

Image cytometry-based detection of aneuploidy by fluorescence in situ hybridization in suspension.

Minderman H, Humphrey K, Arcadi JK, Wierzbicki A, Maguire O, Wang ES, Block AW, Sait SN, George TC, Wallace PK.

Cytometry A. 2012 Sep;81(9):776-84. doi: 10.1002/cyto.a.22101. Epub 2012 Jul 26.

20.

Differentiation of CD8+ T cells into effector cells is enhanced by physiological range hyperthermia.

Mace TA, Zhong L, Kilpatrick C, Zynda E, Lee CT, Capitano M, Minderman H, Repasky EA.

J Leukoc Biol. 2011 Nov;90(5):951-62. doi: 10.1189/jlb.0511229. Epub 2011 Aug 26.

21.

Quantifying nuclear p65 as a parameter for NF-κB activation: Correlation between ImageStream cytometry, microscopy, and Western blot.

Maguire O, Collins C, O'Loughlin K, Miecznikowski J, Minderman H.

Cytometry A. 2011 Jun;79(6):461-9. doi: 10.1002/cyto.a.21068. Epub 2011 Apr 25.

22.

Tenofovir selectively regulates production of inflammatory cytokines and shifts the IL-12/IL-10 balance in human primary cells.

Melchjorsen J, Risør MW, Søgaard OS, O'Loughlin KL, Chow S, Paludan SR, Ellermann-Eriksen S, Hedley DW, Minderman H, Østergaard L, Tolstrup M.

J Acquir Immune Defic Syndr. 2011 Aug 1;57(4):265-75. doi: 10.1097/QAI.0b013e3182185276.

PMID:
21471820
23.

NADPH oxidase limits innate immune responses in the lungs in mice.

Segal BH, Han W, Bushey JJ, Joo M, Bhatti Z, Feminella J, Dennis CG, Vethanayagam RR, Yull FE, Capitano M, Wallace PK, Minderman H, Christman JW, Sporn MB, Chan J, Vinh DC, Holland SM, Romani LR, Gaffen SL, Freeman ML, Blackwell TS.

PLoS One. 2010 Mar 16;5(3):e9631. doi: 10.1371/journal.pone.0009631.

24.

Peroxiredoxin 1 stimulates secretion of proinflammatory cytokines by binding to TLR4.

Riddell JR, Wang XY, Minderman H, Gollnick SO.

J Immunol. 2010 Jan 15;184(2):1022-30. doi: 10.4049/jimmunol.0901945. Epub 2009 Dec 16.

25.

Small ubiquitin-related modifier pathway is a major determinant of doxorubicin cytotoxicity in Saccharomyces cerevisiae.

Huang RY, Kowalski D, Minderman H, Gandhi N, Johnson ES.

Cancer Res. 2007 Jan 15;67(2):765-72.

26.
27.

The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells.

Brooks TA, O'Loughlin KL, Minderman H, Bundy BN, Ford LA, Vredenburg MR, Bernacki RJ, Priebe W, Baer MR.

Invest New Drugs. 2007 Apr;25(2):115-22. Epub 2006 Oct 28.

PMID:
17072745
28.

Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins.

Pawarode A, Shukla S, Minderman H, Fricke SM, Pinder EM, O'Loughlin KL, Ambudkar SV, Baer MR.

Cancer Chemother Pharmacol. 2007 Jul;60(2):179-88. Epub 2006 Oct 10.

PMID:
17031644
29.

Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia.

Minderman H, O'Loughlin KL, Smith PF, Pendyala L, Greco WR, Sweeney KG, Ford LA, Wetzler M, Baer MR.

Cancer Chemother Pharmacol. 2006 Jan;57(1):73-83. Epub 2005 Nov 5.

PMID:
16010591
30.

In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells.

Minderman H, Conroy JM, O'Loughlin KL, McQuaid D, Quinn P, Li S, Pendyala L, Nowak NJ, Baer MR.

Mol Cancer Ther. 2005 Jun;4(6):885-900.

31.

Cyclosporin A is a broad-spectrum multidrug resistance modulator.

Qadir M, O'Loughlin KL, Fricke SM, Williamson NA, Greco WR, Minderman H, Baer MR.

Clin Cancer Res. 2005 Mar 15;11(6):2320-6.

32.

Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival.

Suvannasankha A, Minderman H, O'Loughlin KL, Nakanishi T, Ford LA, Greco WR, Wetzler M, Ross DD, Baer MR.

Br J Haematol. 2004 Nov;127(4):392-8.

PMID:
15521915
33.

Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function.

Suvannasankha A, Minderman H, O'Loughlin KL, Nakanishi T, Greco WR, Ross DD, Baer MR.

Leukemia. 2004 Jul;18(7):1252-7.

PMID:
15208643
34.

Expression of the neural cell adhesion molecule CD56 is not associated with P-glycoprotein overexpression in core-binding factor acute myeloid leukemia.

Suvannasankha A, Minderman H, O'Loughlin KL, Sait SN, Stewart CC, Greco WR, Baer MR.

Leuk Res. 2004 May;28(5):449-55.

PMID:
15068897
35.

Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023.

Minderman H, Brooks TA, O'Loughlin KL, Ojima I, Bernacki RJ, Baer MR.

Cancer Chemother Pharmacol. 2004 May;53(5):363-9. Epub 2004 Jan 27.

PMID:
15060738
37.

Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.

Brooks TA, Minderman H, O'Loughlin KL, Pera P, Ojima I, Baer MR, Bernacki RJ.

Mol Cancer Ther. 2003 Nov;2(11):1195-205. Erratum in: Mol Cancer Ther. 2004 Jan;3(1):101. Brooks, Tracy [corrected to Brooks, Tracy A].

38.

Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.

Baer MR, George SL, Dodge RK, O'Loughlin KL, Minderman H, Caligiuri MA, Anastasi J, Powell BL, Kolitz JE, Schiffer CA, Bloomfield CD, Larson RA.

Blood. 2002 Aug 15;100(4):1224-32.

39.

Flow cytometric analysis of breast cancer resistance protein expression and function.

Minderman H, Suvannasankha A, O'Loughlin KL, Scheffer GL, Scheper RJ, Robey RW, Baer MR.

Cytometry. 2002 Jun 1;48(2):59-65.

40.

Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia.

Bunworasate U, Arnouk H, Minderman H, O'Loughlin KL, Sait SN, Barcos M, Stewart CC, Baer MR.

Blood. 2001 Dec 1;98(12):3492-4.

41.

Time-lapse video reveals immediate heterogeneity and heritable damage among human ileocecal carcinoma HCT-8 cells treated with raltitrexed (ZD1694).

Slocum HK, Parsons JC, Winslow EO, Broderick L, Minderman H, Tóth K, Greco WR, Rustum YM.

Cytometry. 2000 Dec 1;41(4):252-60.

PMID:
11084610
42.

Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350.

Yin MB, Guo B, Vanhoefer U, Azrak RG, Minderman H, Frank C, Wrzosek C, Slocum HK, Rustum YM.

Mol Pharmacol. 2000 Mar;57(3):453-9.

43.

Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells.

Minderman H, Wrzosek C, Cao S, Utsugi T, Kobunai T, Yamada Y, Rustum YM.

Cancer Chemother Pharmacol. 2000;45(1):78-84.

PMID:
10647506
44.

Idarubicin DNA intercalation is reduced by MRP1 and not Pgp.

Smeets ME, Raymakers RA, Vierwinden G, Pennings AH, Boezeman J, Minderman H, de Witte TM.

Leukemia. 1999 Sep;13(9):1390-8.

PMID:
10482990
45.

Topoisomerase-I inhibitor SN-38 can induce DNA damage and chromosomal aberrations independent from DNA synthesis.

Voigt W, Matsui S, Yin MB, Burhans WC, Minderman H, Rustum YM.

Anticancer Res. 1998 Sep-Oct;18(5A):3499-505.

PMID:
9858931
46.

Rational design of irinotecan administration based on preclinical models.

Minderman H, Cao S, Rustman YM.

Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):22-30.

47.

Evaluation of topoisomerase I catalytic activity as determinant of drug response in human cancer cell lines.

Voigt W, Vanhoefer U, Yin MB, Minderman H, Schmoll HJ, Rustum YM.

Anticancer Res. 1997 Sep-Oct;17(5A):3707-11.

PMID:
9413228
48.

d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.

Vanhoefer U, Cao S, Minderman H, Toth K, Skenderis BS 2nd, Slovak ML, Rustum YM.

Clin Cancer Res. 1996 Dec;2(12):1961-8.

49.

A unique human ovarian carcinoma cell line expressing CD34 in association with selection for multidrug resistance.

Minderman H, Vanhoefer U, Toth K, Minderman MD, Rustum YM.

Cancer. 1996 Dec 1;78(11):2427-36.

PMID:
8941015
50.

DiOC2(3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux.

Minderman H, Vanhoefer U, Toth K, Yin MB, Minderman MD, Wrzosek C, Slovak ML, Rustum YM.

Cytometry. 1996 Sep 1;25(1):14-20.

Supplemental Content

Loading ...
Support Center